

Table 2: Hematologic parameters of young patients with sickle/beta-thalassemia at study entry and exit for patients who completed 24 months of hydroxyurea therapy (n: 12)

	Study entry		24 months of HU therapy		p-value
	Mean \pm SD	Median (min-max)	Mean \pm SD	Median (min-max)	
Hb (g/dl)	9.2 \pm 0.7	9.3 (7.6 - 10.0)	9.9 \pm 0.9	9.7 (7.9 - 10.9)	0.012
HbF (%)	9.5 \pm 6.1	8.7 (2.2 - 24.2)	23.5 \pm 9.9	22.6 (6.2 - 39.6)	< 0.001
MCV (fl)	66.6 \pm 3.8	67.3 (60.9 - 72.0)	86.1 \pm 10.7	85.4 (72.0 - 111.0)	< 0.001
MCH (pg)	21 \pm 1.2	21.2 (19.3 - 22.9)	27.7 \pm 2.7	27.7 (23.0 - 33.5)	< 0.001
WBC ($10^9/l$)	9.2 \pm 3.3	9.1 (3.68 - 15.0)	6.6 \pm 12.8	7.3 (4.7 - 8.0)	0.005
PLT ($10^9/l$)	359 \pm 172	313 (137 - 669)	256 \pm 112	273 (96 - 502)	0.008
RETIC (%)	8.7 \pm 4.0	7.5 (2.5 -17.5)	5.2 \pm 3.0	4.6 (1.8 - 12.0)	0.017
Total bilirubin (mg/dl)	2.3 \pm 1.5	1.8 (0.8 - 6.1)	1.6 \pm 0.5	1.3 (1.0 - 2.6)	0.023
LDH (IU/l)	415 \pm 164	374 (245 - 831)	354 \pm 129	292 (245 - 684)	0.108

SD: standard deviation, HU: hydroxyurea, N: number of participants, Hb: hemoglobin, HbF: hemoglobin F, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, WBC: white blood cell count, PLT: platelet count, RETIC: reticulocyte count, LDH: lactate dehydrogenase.